Mayo Clinic recently launched two new companies, Anumana Inc. and Lucem Health Inc., on Wednesday, April 14, 2021, in support of its Remote Diagnostics and Management Platform (RDMP).
According to Fierce Healthcare, Mayo Clinic and its partners invested around $30 million for the project. Of this amount, $25.7 million was granted to Anumana Inc. in its Series A funding round. Lucem Health Inc.’s $6 million was likewise completed in a Series A investment round.
The new companies will reportedly seek to analyze data from remote monitoring devices and diagnostic tools under the careful guidance of artificial intelligence. The launching of the two companies aims to provide a more precise approach to physiological data to medical professionals, allowing them to make decisions faster, and by extension, deliver essential care to patients.
In a report released by Healthcare IT News, the Rochester, Minnesota-based clinic’s new Remote Diagnostics and Management Platform was made to combine powerful artificial intelligence algorithms alongside existing health data to support diagnostic insights, clinical decision support tools, and to provide care recommendations.
In a statement by John Halamka, MD, President of the Mayo Clinic Platform, he said, “With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings.”
“The platforms will also enable patients to take more control of their health and make better decisions based on insights delivered directly through them,” continue Halamka in Mayo Clinic’s press release.
Mayo Clinic will provide the two new ventures with extensive access to medical knowledge to come up with the digital tools essential in arming healthcare workers with the right treatment options for their patients.
Anumana Inc., on the one hand, seeks to develop and commercialize algorithms that primarily make use of artificial intelligence with the help of nference as well as Mayo’s wealth of medical data. In particular, the company will double down on neural network algorithms based on the data provided, reports Fierce Healthcare.
Through the AI-guided platform and its algorithms, Anumana aims not just to detect “silent” conditions at a much earlier stage, they also wish to further treatment of this type of disease.
Meanwhile, Lucem Health Inc. is tasked to “collect, orchestrate, and curate data from any device.” Using artificial intelligence technologies and algorithms, the platform will have the ability to connect remote patient telemetry devices.
With Lucem Health Inc.’s platform, it can deliver more streamlined approaches and services to make the overall workflow seamless, especially when it comes to real-work applications, notes Healthcare IT News.
